Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its antibody-coupled T-cell receptor technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy.

Legal

United States

Cambridge, MA, USA

Waltham, MA, USA

Cogent Biosciences

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

F-Prime Capital Partners

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining F-Prime Capital Partners Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the F-Prime Capital Partners network as they come up.

You can always update this information later.

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a F-Prime Capital Partners company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.